Abecma US Revenue: $77 million in the third quarter, reflecting a 42% growth over the prior quarter. Projected Abecma US Revenue for 2024: Approximately $240 to $250 million. Collaboration Arrangement ...

Seventy Bio, Inc. ( (TSVT) ) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its ...

The latest announcement is out from 2seventy bio ( (TSVT) ). 2seventy bio reported impressive third-quarter results with a 42% increase in ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

2seventy Bio focuses on pioneering cell and gene therapies. Its lead product, Abecma, is a chimeric antigen receptor (CAR) ...

CAMBRIDGE, Mass., November 12, 2024--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent ...

The firm acknowledged that 2Seventy Bio's third-quarter sales of its Abecma product in the United States, reported at $77 million, exceeded the consensus estimates of $70 million. The company also ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

Abecma’s review was delayed after the FDA rejected a first filing in May last year, but it’s hoped that the drug could be a significant step forward in the treatment of this incurable condition.

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy for multiple myeloma ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...